Click here
Thursday 23 May 2013 Register   Login
Search 
  
You are here:
Home
News
Latest issue
Subscribe
Email bulletin
Suppliers Guide
Advertise
Contact us
New neurology product
Hospital Pharmacy Europe is assisting with a survey on messaging for a new neurology product. Click here
LATEST ISSUE
Contamination control and preparation of anticancer drugs, medicines reconciliation, Ruconest drug evaluation, ivacaftor for cystic fibrosis , oxycodone-naloxone prolonged-release tablets, IV chemotherapy, capsaicin in the treatment of severe neuropathic pain, alitretinoin in severe chronic hand eczema, Zyclara for actinic keratoses
Industry News
Tuesday 21 May
Tiotropium in symptomatic asthma patients
Tiotropium delivered by the Respimat Soft Mist Inhaler increases time to first severe exacerbation (p=0.03) and first episode of asthma worsening (p<0.001) compared with placebo in symptomatic asthma patients receiving standard care treatments (ICS/LABA). These improvements were independent of age, allergic status, smoking status and bronchodilator response.
Tuesday 21 May
Phase III trial of regorafenib in patients with advanced liver cancer
Bayer HealthCare has announced that the company has started to enrol patients in an international Phase III trial to evaluate the efficacy and safety of regorafenib for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib treatment.
Tuesday 21 May
Phase III results for afatinib and ninedanib
Boehringer Ingelheim has announced the upcoming presentation of data from 14 abstracts involving three of the company’s investigational oncology compounds – afatinib, nintedanib and volasertib. Results, to be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, 31 May - 4 June, 2013, are from Boehringer Ingelheim’s robust oncology pipeline.
See all Industry News »
CENTRAL NERVOUS SYSTEM
Rufinamide in Lennox-Gastaut syndrome
Wednesday 17 October 2012
Rufinamide is an anti-epileptic drug that received marketing authorisation as adjunctive therapy in Lennox-Gastaut syndrome (LGS) from the European commission in January 2007 and the FDA in November 2008. It has a different mode of action from other anti-epileptic drugs: it modulates the frequency of sodium-dependent neuronal action potentials, although the precise mechanism is yet to be determined. The Cmax is approximately six hours and the half-life is six-to-ten hours in healthy volunteers. Sodium valproate may decrease the clearance. It is not strongly protein bound. Although licensed only for the treatment of LGS, efficacy has also been demonstrated in other epilepsy syndromes and seizure types, notably partial seizures.
MRI findings dispute blood flow and MS correlation
Wednesday 22 August 2012
While researchers have speculated that changes in brain blood flow due to vein abnormalities contribute to multiple sclerosis (MS) disease severity, a study published online Aug. 21 in Radiology has demonstrated this may not be the case as these abnormalities were shown not to be specific to MS.
ONCOLOGY
Merck Serono: non-small cell lung cancer Phase III trial
Friday 17 May 2013
Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomised Phase III START* trial of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). These results will be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago.
Oncology portfolio
Friday 17 May 2013
Bayer HealthCare has announced that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently US Food and Drug Administration (FDA) approved product Xofigo® (radium 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 - June 4, in Chicago, IL (USA).
Roundtable
Roundtable
 
Iron sucrose complex drugs - identical or just similar?
Continuing the series of HPE Pharmacist Roundtable Meetings on complex non-biological drugs, a panel of senior European hospital pharmacists and renal specialists met in Utrecht, The Netherlands, to discuss insights and advances in the field and to consider the evidence for therapeutic differences between iron sucrose originator and iron sucrose similar preparations.
 
 
Regulation of complex molecules 
Roundtable meetings in London and Paris discussed evidence for therapeutic differences between the originator iron sucrose and iron sucrose similars and called for a new regulatory pathway for non-biological complex molecules.
 
Supplements

HPE supplements are created to provide readers with dedicated resources and materials for specific areas of hospital pharmacy. Click on the images below to access the latest supplements:
CareFusion Handbook, BD Medical Handbook, Hospital Vascular Access Europe and Hospital Cardiology Europe
 
CareFusion+Handbk BD+Handbk
 
HVAE HCE+2+

Advertisement Features

© Campden Publishing Limited 2013
Site Map | Accessibility | Terms & Conditions | Privacy Policy | Contacts
Campden Publishing Ltd., 140 London Wall London EC2Y 5DN, is a company registered in the United Kingdom with Reg. No. 2147432
www.campden.com

Web design, hosting and programming by ModeZero